CG Invites 
Welcome,         Profile    Billing    Logout  
 6 Products   6 Diseases   6 Products   995 Trials   3123 News 


«12...1112131415161718192021...5253»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca, AiRuiKa (camrelizumab) / HLB Bio Group
    Vitamin A Metabolism Induces Ferroptosis to Enhance Immune Therapy Efficacy in HR+/HER2- Breast Cancer (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_600;    
    P2, P3
    Our study represents the earliest efforts to decipher the microenvironmental landscape and the mechanisms underlying the response to ICB in HR+/HER2- breast cancer at single-cell resolution. We unraveled a HR+/HER2- breast cancer-specific Vitamin A-ferroptosis axis that mediated immunotherapy response and constructed a robust immunotherapy efficacy prediction score based on this Vitamin A-ferroptosis axis.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open:  FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov) -  Nov 1, 2023   
    P2,  N=120, Recruiting, 
    Therefore, Camrelizumab combined with BeGe chemotherapy patients shows encouraging clinical efficacy and safety in R/R HL, and has no significant effect on stem cell collection, which is worthy of further study. Not yet recruiting --> Recruiting
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest, AiRuiKa (camrelizumab) / HLB Bio Group
    Journal, PD(L)-1 Biomarker, IO biomarker:  Anti-PD-1 treatment protects against seizure by suppressing sodium channel function. (Pubmed Central) -  Oct 31, 2023   
    Not yet recruiting --> Recruiting Our study reveals that neuronal PD-1 plays an important role in epilepsy and that anti-PD-1 treatment protects against seizures by suppressing sodium channel function, identifying anti-PD-1 treatment as a novel therapeutic strategy for epilepsy.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial initiation date:  NEOPCOSCC: Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma (clinicaltrials.gov) -  Oct 23, 2023   
    P3,  N=309, Not yet recruiting, 
    Camrelizumab plus rivoceranib showed a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma, presenting as a new and effective first-line treatment option for this population. Initiation date: Aug 2023 --> Nov 2023
  • ||||||||||  ivaltinostat IV (CG-745) / CG Invites
    Enrollment closed:  Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule (clinicaltrials.gov) -  Oct 23, 2023   
    P1,  N=32, Active, not recruiting, 
    Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Aug 2024 Not yet recruiting --> Active, not recruiting
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    Journal, PD(L)-1 Biomarker:  Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M. (Pubmed Central) -  Oct 23, 2023   
    We present a case of a stage IV lung adenocarcinoma patient harboring EGFR L858R, acquired T790M after treatment with first-line gefitinib...A combination targeted therapy of osimertinib plus alectinib was initiated, with a progression-free survival of 5?months without any serious adverse reaction...Then therapy was changed to pemetrexed combined with bevacizumab plus camrelizumab, but no obvious effect was observed...Our case shows that EML4-ALK fusion is a rare but critical resistance mechanism to osimertinib, and C797S mutation in cis may be an underlying mechanism of acquired resistance mutation in double TKIs therapy. Furthermore, molecular detection and rebiopsy play important roles in the selection of therapeutic strategies when the disease progresses.
  • ||||||||||  AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
    Journal:  Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration. (Pubmed Central) -  Oct 11, 2023   
    This case may offer new insight to clinicians on the pathogenesis of anti-PD-1-induced OLR. More critically, it may provide some ideas for a more precise anti-PD therapy or corresponding combination therapy for patients becoming resistant to immunotherapy due to exhausted CD4+ T-cell responses in the tumor microenvironment.
  • ||||||||||  ivaltinostat IV (CG-745) / CG Invites
    Trial primary completion date:  A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) -  Oct 10, 2023   
    P1b/2,  N=70, Recruiting, 
    More critically, it may provide some ideas for a more precise anti-PD therapy or corresponding combination therapy for patients becoming resistant to immunotherapy due to exhausted CD4+ T-cell responses in the tumor microenvironment. Trial primary completion date: Sep 2023 --> Feb 2025
  • ||||||||||  AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
    Journal, Metastases:  The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China. (Pubmed Central) -  Oct 6, 2023   
    The 2 years progression-free survival (PFS) was 67.0% (95% CI: -0.05, 0.00) and overall survival (OS) was 55.3% (95% CI: -0.05, 0.01) for the 16 patients who had received camrelizumab. Conclusions-This study demonstrates that camrelizumab treatment in patients with advanced cancers and HIV/AIDS was feasible and the clinical outcomes were acceptable.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, AiRuiKa (camrelizumab) / HLB Bio Group
    Review, Journal:  Nasopharyngeal Carcinoma: Case Presentation and Literature Review of Treatment Innovation with Immunotherapy. (Pubmed Central) -  Sep 29, 2023   
    Several clinical trials have investigated the efficacy of anti-programmed cell death protein 1 antibodies such as pembrolizumab, nivolumab, and camrelizumab with promising results. Treatment of recurrent and metastatic NPC remains a challenge; however, the advent of immunotherapy has provided additional options and potential for preventative and therapeutic measures.
  • ||||||||||  paclitaxel / Generic mfg.
    Paclitaxel liposome plus immunotherapy for unresectable advanced non-small cell lung cancer: a real-world study (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1124;    
    98% of patients were co-administered platinum, with 91 receiving carboplatin, 4 receiving nedaplatin, and 3 receiving cisplatin...The most common adverse events included bone marrow suppression, gastrointestinal reactions, and liver function abnormalities. Conclusions Paclitaxel liposome-based chemotherapy plus immunotherapy demonstrated substantial effectiveness and safety for advanced NSCLC in the real-world setting.
  • ||||||||||  AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
    Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases:  Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer. (Pubmed Central) -  Sep 23, 2023   
    Conclusions Paclitaxel liposome-based chemotherapy plus immunotherapy demonstrated substantial effectiveness and safety for advanced NSCLC in the real-world setting. Our results suggest that the trough concentration level of camrelizumab might be a risk factor for the occurrence of irAEs in advanced lung cancer, and using the immunotherapy as early as possible may bring better clinical outcomes.
  • ||||||||||  AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
    ABNORMAL ULTRASOUND FEATURES AND CLINICAL MANIFESTATIONS OF THYROID METASTATIC CARCINOMA: A RARE CASE REPORT () -  Sep 20, 2023 - Abstract #ATA2023ATA_507;    
    Since she was in the end stage of malignant tumor, the disease progressed rapidly and the prognosis was poor. For tumor patients who use immune checkpoint inhibitors (ICI), when experiencing abnormal thyroid function or thyroid ultrasound morphology, endocrine immune?related adverse events of ICIs are often the first consideration, however it is also necessary to be wary of distant metastasis of tumors to the thyroid gland.
  • ||||||||||  AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm). (Pubmed Central) -  Sep 19, 2023   
    For tumor patients who use immune checkpoint inhibitors (ICI), when experiencing abnormal thyroid function or thyroid ultrasound morphology, endocrine immune?related adverse events of ICIs are often the first consideration, however it is also necessary to be wary of distant metastasis of tumors to the thyroid gland. In patients with unresectable multiple nodular and large HCC (single nodular diameter of >5 cm), TACE combined with target therapy and immunotherapy is safe and effective.